Growth Hormone Stack

The community figured this one out before the researchers did. CJC-1295 without DAC, also called Mod GRF 1-29 (parent GRF(1-29) CAS 83930-13-6), is a 29-amino-acid GHRH analog modified at four positions to resist enzymatic breakdown. Its closest human data comes from Frohman et al. (1992, PMID 1379256), where hGRF(1-29) injected subcutaneously twice daily normalized GH and IGF-1 in older men. The mechanism is direct. Mod GRF 1-29 binds the GHRH receptor on pituitary somatotroph cells, triggering a cAMP-driven GH release that peaks around 15 to 30 minutes and clears within the hour. That short action window is the entire point. Unlike the DAC version (which circulates for days and produces tonic GH elevation), the no-DAC form preserves your natural pulsatile rhythm. Real-world use centers on the Mod GRF + Ipamorelin stack. Community consensus across hundreds of r/Peptides threads and practitioner networks puts the standard protocol at 100 mcg of each, co-injected subcutaneously once or twice daily on a fasted stomach before bed. Users consistently report improved sleep within the first two weeks, faster recovery by week three, and visible body composition changes by month two. Vendor quality is a known problem; Finnrick Analytics found purity as low as 68.75% across 244 samples from 47 vendors. No FDA-approved form exists, and no Phase I, II, or III trial has been completed for Mod GRF 1-29 specifically.

Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998, PMID 9849822) explains why ipamorelin became the default starter peptide for growth hormone optimization. Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Human pharmacokinetic modeling by Svensson et al. (1999, PMID 10496658) confirmed a 2-hour half-life, roughly 95% subcutaneous bioavailability, and a dose-response ceiling around 300 to 400 mcg per injection. Going higher doesn't produce a bigger pulse. The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a synergistic GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response. Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only finished human RCT (Phase 2b for postoperative ileus) failed its primary endpoint versus placebo. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Andersen et al. 1999, PMID 10828840) and cachexia (2024 ferret model, PMID 39043357) looks promising but hasn't been replicated in humans.